GAS5 and metabolic dysfunction-associated steatotic liver disease: Han et al. revealed that GAS5 expression was strongly correlated with liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) (Han et al., 2020), and plasma GAS5 expression was significantly higher in patients with advanced stages than in non-advanced stages (Han et al., 2020).